• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Servier (Group)

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 150 countries and a total revenue of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for its development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory, and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. *

 

	Start	1954-01-01 established
	Industry	pharmaceutical
	Industry 2	cancer drug
	Street	50 rue Carnot
	City	92284 Suresnes Cedex
	Tel	+33-1-5572-6000
		Address record changed: 2020-12-02
Basic data	Employees	H: 10,001 to 50,00 (2020-04-03)
	Currency	EUR
	Annual sales	4,600,000,000 (revenue, total, consolidated (2019) 2019-12-31)
		* Document for �About Section�: Servier. (10/6/20). "Press Release: The Servier Group Accelerates Its Digital Transformation and Has Named Virginie Dominguez as Chief Digital Officer". Paris.
		Record changed: 2020-12-25

Advertisement

More documents for Servier (Group)

• [1] Thermo Fisher Scientific Inc.. (10/29/18). "Press Release: Thermo Fisher Scientific Announces Collaboration to Simplify Analysis of Complex Therapeutic Proteins". Sunnyvale, CA....
• [2] GeNeuro S.A.. (9/18/18). "Press Release: GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier". Paris & Geneva....
• [3] GeNeuro S.A.. (12/21/17). "Press Release: GeNeuro To Receive €12 Million Milestone Payment from Servier for Final Patient Visit in GNbAC1 CHANGE-MS Phase 2b Study". Geneva....
• [4] Servier. (11/2/17). "Press Release: Servier Germany to Co-promote Novartis’ Blockbuster Entresto"....
• [5] Servier. (2/14/17). "Press Release: Servier and GAIA Extend Their Partnership to Provide Patients around the World with Deprexis, an Internet-based Cognitive Behavioral Therapy for Depression". Suresnes & Hamburg....
• [6] Pieris Pharmaceuticals, Inc.. (1/5/17). "Press Release: Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance". Boston, MA & Suresnes....
• [7] Selexis S.A.. (6/29/16). "Press Release: Symphogen A/S Advances Sym015 into Clinical Development Using Selexis SGEs (Selexis Genetic Elements)". Geneva....
• [8] Servier. (12/18/15). "Press Release: GeNeuro Announces the Launch of Phase IIb Proof-of-Concept Study with GNbAC1 in Multiple Sclerosis and Servier Equity Investment". Geneva & Suresnes....
• [9] Servier. (12/7/15). "Press Release: Servier Announces Expansion of Collaboration for the Development and Commercialization of Anticancer Drug Candidates Targeting Apoptosis". Suresnes....
• [10] Servier. (6/15/15). "Press Release: Taiho Pharmaceutical Co., Ltd. and Servier Enter into a License Agreement for Development and Commercialization of an Oral Anticancer Drug TAS-102 in Europe". Tokyo....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.